Dr. Valente, our Managing Partner and Co-Founder, contributed to the conversation with Pharmaceutial Executive (https://bit.ly/3i5p203) about how to overcome common roadblocks to global expansion in Pharma and Biotech.

"Last year was a down year for mergers and acquisitions (M&As) because of the pandemic, but biopharma deal-making is once again on the rise, evidenced by Gilead Sciences finalizing its purchase of Immunomedics. Gilead is one of many global biopharmaceutical companies hoping to find footing in the United States for two reasons: Biotech innovation has skyrocketed and U.S. tax penalties have been mitigated."
To learn more, read the article at:
Comments